Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CorMedix Inc.CRMD · Entity 5280 | Chief Financial Officer | September 30, 2019 | October 01, 2019 |
| Elite Express Holding Inc.ETS · Entity 7312 | See Remarks | August 20, 2025 | August 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CorMedix Inc.
Report date September 30, 2019 · Filed October 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,517 |
Reported balance
After 2019-09-30 transaction · row 1
1 source rowRow 1 · 2019-09-30 · Purchase · Acquired 1,000 · Balance 27,517 |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.30 · Expires 2029-01-10 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2019-09-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 20,000 F1: These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2027-01-30 | Direct | 33,000 |
Reported balance
Holding disclosure · report date 2019-09-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 33,000 F2: The option vests based on certain performance milestones. The option will be forfeited if such milestones are not met by certain dates. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2027-01-30 | Direct | 37,000 |
Reported balance
Holding disclosure · report date 2019-09-30 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 37,000 F3: The option vests in four equal annual installments beginning on the first anniversary of the vesting commencement date, 2/1/18, subject to continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones.
F2: The option vests based on certain performance milestones. The option will be forfeited if such milestones are not met by certain dates.
F3: The option vests in four equal annual installments beginning on the first anniversary of the vesting commencement date, 2/1/18, subject to continued employment.
Elite Express Holding Inc.
Report date August 20, 2025 · Filed August 20, 2025
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2019 Filed Oct 1, 2019 21:13 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 1,000 | $6.88 | $6,879.30 |
DisclosureSEC source: 0001213900-19-019412 · doc4.xml · nonDerivative · entry 1 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,517 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 20:10 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 1,000 | $8.18 | $8,180.00 |
DisclosureSEC source: 0001213900-19-016280 · doc4.xml · nonDerivative · entry 1 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,517 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 20:09 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 1,000 | $8.18 | $8,180.00 |
DisclosureSEC source: 0001213900-19-016279 · doc4.xml · nonDerivative · entry 1 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,517 Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 20:49 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 100 | $9.35 | $935.00 |
DisclosureSEC source: 0001654954-19-003866 · section16.xml · nonDerivative · entry 1 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,517 F1 · balance_after: The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:19 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 100,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000384 · section16.xml · derivative · entry 2 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-10 F1 · derivative.exercise_date: These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. Read SEC document |
| November 27, 2018 Filed Nov 27, 2018 21:53 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 25,000 | $1.17 | $29,212.50 |
DisclosureSEC source: 0001654954-18-013260 · section16.xml · nonDerivative · entry 1 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,083 Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:02 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 45,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001654954-18-001716 · section16.xml · derivative · entry 2 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-02-16 F1 · derivative.exercise_date: The options vest 25% on the date of grant (2/16/2018), and 25% on the first, second and third anniversaries of the date of grant, subject to Optionee's continued service through such date. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:09 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 52,083 | $0.48 | $24,999.84 |
DisclosureSEC source: 0001654954-17-011650 · section16.xml · nonDerivative · entry 1 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,083 F1 · date: Purchase was contracted on November 17, 2017, but not closed until December 12, 2017. Read SEC document |
| May 15, 2017 Filed May 17, 2017 20:06 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 50,000 | $0.50 | $24,950.00 |
DisclosureSEC source: 0001354488-17-000513 · issuerdirect_section16.xml · nonDerivative · entry 1 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| January 30, 2017 Filed Feb 9, 2017 21:28 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to buy Common Stock) · Derivative | 185,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001354488-17-000243 · issuerdirect_section16.xml · derivative · entry 2 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2027-01-30 F1 · date: The option was granted on 1/30/17 contingent upon the Reporting Person commencing employment on 2/1/17. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on the first anniversary of the vesting commencement date, 2/1/18, subject to continued employment. Read SEC document |
| January 30, 2017 Filed Feb 9, 2017 21:28 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to buy Common Stock) · Derivative | 165,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001354488-17-000243 · issuerdirect_section16.xml · derivative · entry 1 Cook Robert W. · CIK 0001235438 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2027-01-30 F1 · date: The option was granted on 1/30/17 contingent upon the Reporting Person commencing employment on 2/1/17. F2 · derivative.exercise_date: The option vests based on certain performance milestones. The option will be forfeited if such milestones are not met by certain dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.